Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment
Nephrotic syndrome affects about 2–7 per 100,000 children yearly and accounts for less than 15% of end stage kidney disease. Steroids still represent the cornerstone of therapy achieving remission in 75–90% of the cases The remaining part result as steroid resistant nephrotic syndrome, characterized...
Main Authors: | Andrea Angeletti, Maurizio Bruschi, Xhuliana Kajana, Edoardo La Porta, Sonia Spinelli, Gianluca Caridi, Francesca Lugani, Enrico Eugenio Verrina, Gian Marco Ghiggeri |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213203/full |
Similar Items
-
New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
by: Biswanath Basu, et al.
Published: (2022-02-01) -
State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs
by: Flavio Vincenti, et al.
Published: (2023-07-01) -
Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis
by: Decimo Silvio Chiarenza, et al.
Published: (2025-01-01) -
Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol
by: Francesco Emma, et al.
Published: (2021-11-01) -
Case Report: Multisystem inflammatory syndrome in children with associated proximal tubular injury
by: Silvia Maria Orsi, et al.
Published: (2023-06-01)